Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
University of Arkansas
Study ID
NCT07539155
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Borderline Resectable/Unresectable Pancreatic Cancer
  • Non Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intratumoral MMR Injection — BIOLOGICAL
    A single dose (0.5 mililiter) of MMR vaccine will be injected under endoscopic ultrasound guidance in the GI laboratory at UAMS under sedation as prescribed by the interventional gastroenterologist. The injection will be at least 6 weeks but no later than 12 weeks post completion of chemo-radiation therapy.

Study Details

By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.

Key Dates

First listed
Apr 20, 2026
Start date
Jun 26, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intratumoral MMR Injection

Primary Outcome Measure

Intratumoral T-Cell Response [ Time Frame: Baseline to 4 weeks post injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Arkansas for Medical SciencesLittle RockArkansas72205
Maroof Zafar
501-686-8274
Joseph Holley
501-686-8274

Find similar trials in Little Rock, AR

By research site
University of Arkansas for Medical Sciences· Little Rock, AR